{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T02:29:24Z","timestamp":1726453764783},"reference-count":111,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2010,6,26]],"date-time":"2010-06-26T00:00:00Z","timestamp":1277510400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nervenarzt"],"published-print":{"date-parts":[[2011,4]]},"DOI":"10.1007\/s00115-010-3059-8","type":"journal-article","created":{"date-parts":[[2010,6,24]],"date-time":"2010-06-24T17:59:15Z","timestamp":1277402355000},"page":"415-430","source":"Crossref","is-referenced-by-count":12,"title":["Einsatz intraven\u00f6ser Immunglobuline in der Neurologie"],"prefix":"10.1007","volume":"82","author":[{"given":"M.","family":"Stangel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Gold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,6,26]]},"reference":[{"key":"3059_CR1","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1007\/s00415-004-0495-z","volume":"251","author":"Achiron","year":"2004","unstructured":"Achiron A, Kishner I, Dolev M et al (2004) Effect of intravenous immunoglobulin treatment on pregnancy and post-partum related relapses in multiple sclerosis. J Neurol 251:1133\u20131137","journal-title":"J Neurol"},{"key":"3059_CR2","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1001\/archneur.61.10.1515","volume":"61","author":"Achiron","year":"2004","unstructured":"Achiron A, Kishner I, Sarova-Pinhas I et al (2004) Intravenous immunoglobulin treatment following the first demyelinating event suggestive of multiple sclerosis. A randomized, double-blind, placebo-controlled trial. Arch Neurol 61:1515\u20131520","journal-title":"Arch Neurol"},{"key":"3059_CR3","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/j.1365-2249.2004.02412.x","volume":"136","author":"Ameratunga","year":"2004","unstructured":"Ameratunga R, Sinclair J, Kolbe J (2004) Increased risk of adverse events when changing intravenous immunoglobulin preparations. Clin Exp Immunol 136:111\u2013113","journal-title":"Clin Exp Immunol"},{"key":"3059_CR4","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1159\/000096493","volume":"56","author":"Arias","year":"2006","unstructured":"Arias M, Dapena D, Arias-Rivas S et al (2006) Rasmussen encephalitis in the sixth decade: magnetic resonance image evolution and immunoglobulin response. Eur Neurol 56:236\u2013239","journal-title":"Eur Neurol"},{"key":"3059_CR5","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1017\/S0317167100053932","volume":"31","author":"Bakker","year":"2004","unstructured":"Bakker J, Metz L (2004) Devic\u2019s neuromyelitis optica treated with intravenous gamma globulin (IVIG). Can J Neurol Sci 31:265\u2013267","journal-title":"Can J Neurol Sci"},{"key":"3059_CR6","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1007\/s12026-007-0003-5","volume":"38","author":"Ballow","year":"2007","unstructured":"Ballow M (2007) Safety of IGIV therapy and infusion-related adverse events. Immunol Res 38:122\u2013132","journal-title":"Immunol Res"},{"key":"3059_CR7","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1002\/ana.21802","volume":"66","author":"Bennett","year":"2009","unstructured":"Bennett JL, Lam C, Kalluri SR et al (2009) Intrathecal pathogenic anti-aquaporin-4 antibodies in early neuromyelitis optica. Ann Neurol 66:617\u2013629","journal-title":"Ann Neurol"},{"key":"3059_CR8","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1093\/brain\/awh415","volume":"128","author":"Bien","year":"2005","unstructured":"Bien CG, Granata T, Antozzi C et al (2005) Pathogenesis, diagnosis and treatment of Rasmussen encephalitis: a European consensus statement. Brain 128:454\u2013471","journal-title":"Brain"},{"key":"3059_CR9","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1212\/01.WNL.0000143066.58498.BA","volume":"63","author":"Blaes","year":"2004","unstructured":"Blaes F, Schmitz K, Tschernatsch M et al (2004) Autoimmune etiology of complex regional pain syndrome (M.\u00a0Sudeck). Neurology 63:1734\u20131736","journal-title":"Neurology"},{"key":"3059_CR10","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1002\/ana.21837","volume":"66","author":"Bradl","year":"2009","unstructured":"Bradl M, Misu T, Takahashi T et al (2009) Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo. Ann Neurol 66:630\u2013643","journal-title":"Ann Neurol"},{"key":"3059_CR11","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/mus.21236","volume":"39","author":"Bril","year":"2009","unstructured":"Bril V, Katzberg H, Donofrio P et al (2009) Electrophysiology in chronic inflammatory demyelinating polyneuropathy with IGIV. Muscle Nerve 39:448\u2013455","journal-title":"Muscle Nerve"},{"key":"3059_CR12","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s00415-009-0969-0","volume":"256","author":"Caress","year":"2009","unstructured":"Caress JB, Hobson-Webb L, Passmore LV et al (2009) Case-control study of thromboembolic events associated with IV immunoglobulin. J Neurol 256:339\u2013342","journal-title":"J Neurol"},{"key":"3059_CR13","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1093\/rheumatology\/kem345","volume":"47","author":"Caro","year":"2008","unstructured":"Caro XJ, Winter EF, Dumas AJ (2008) A subset of fibromyalgia patients have findings suggestive of chronic inflammatory demyelinating polyneuropathy and appear to respond to IVIg. Rheumatology 47:208\u2013211","journal-title":"Rheumatology"},{"key":"3059_CR14","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1056\/NEJM199807303390501","volume":"339","author":"Confavreux","year":"1998","unstructured":"Confavreux C, Hutchinson M, Hours MM et al (1998) Rate of pregnancy-related relapse in multiple sclerosis. N Engl J Med 339:285\u2013291","journal-title":"N Engl J Med"},{"key":"3059_CR15","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1212\/01.WNL.0000159399.81861.D5","volume":"64","author":"Cree","year":"2005","unstructured":"Cree BAC, Lamb S, Morgan K et al (2005) An open label study of the effects of rituximab in neuromyelitis optica. Neurology 64:1270\u20131272","journal-title":"Neurology"},{"key":"3059_CR16","doi-asserted-by":"crossref","unstructured":"Danieli MG, Calcabrini L, Calabrese V et al (2010) Intravenous immunoglobulin as add on treatment with mycophenolate mofetil in severe myositis. Autoimmun Rev (in press)","DOI":"10.1016\/j.autrev.2009.04.003"},{"key":"3059_CR17","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/ana.20892","volume":"60","author":"Dauvilliers","year":"2006","unstructured":"Dauvilliers Y (2006) Follow-up of four narcolepsy patients treated with intravenous immunoglobulins. Ann Neurol 60:153\u2013153","journal-title":"Ann Neurol"},{"key":"3059_CR18","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1002\/ana.20339","volume":"56","author":"Dauvilliers","year":"2002","unstructured":"Dauvilliers Y, Carlander B, Rivier F et al (2002) Successful management of cataplexy with intravenous immunoglobulins at narcolepsy onset. Ann Neurol 56:905\u2013908","journal-title":"Ann Neurol"},{"key":"3059_CR19","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1212\/01.wnl.0000234063.51897.20","volume":"67","author":"Delmont","year":"2006","unstructured":"Delmont E, Azulay JP, Giorgi R et al (2006) Multifocal motor neuropathy with and without conduction block. A single entity? Neurology 67:592\u2013596","journal-title":"Neurology"},{"key":"3059_CR20","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1136\/jnnp.2003.033399","volume":"75","author":"Dodel","year":"2004","unstructured":"Dodel R, Du Y, Depboylu C et al (2004) Intravenous immunoglobulins containing antibodies against \u03b2-amyloid for the treatment of Alzheimer\u2019s disease. J Neurol Neurosurg Psychiatry 75:1472\u20131474","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"3059_CR21","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/ana.10253","volume":"52","author":"Dodel","year":"2002","unstructured":"Dodel R, Hampel H, Depboylu C et al (2002) Human antibodies against amyloid \u03b2 peptide: A potential treatment for Alzheimer\u2019s disease. Ann Neurol 52:253\u2013256","journal-title":"Ann Neurol"},{"key":"3059_CR22","doi-asserted-by":"crossref","unstructured":"Eftimov F, Winer JB, Vermeulen M et al (2009) Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev CD001797","DOI":"10.1002\/14651858.CD001797.pub2"},{"key":"3059_CR23","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1111\/j.1468-1331.2008.02246.x","volume":"15","author":"Elovaara","year":"2008","unstructured":"Elovaara I, Apostolski S, Doorn P van et al (2008) EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases. Eur J Neurol 15:893\u2013908","journal-title":"Eur J Neurol"},{"key":"3059_CR24","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/j.1468-1331.2006.01552.x","volume":"14","author":"Farbu","year":"2007","unstructured":"Farbu E, Rekand T, Vik-Mo E et al (2007) Post-polio syndrome patients treated with intravenous immunoglobulin: a double-blind randomized controlled pilot study. Eur J Neurol 14:60\u201365","journal-title":"Eur J Neurol"},{"key":"3059_CR25","unstructured":"Fazekas F, Lublin FD, Li D et al (2010) Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: a dose-finding trial. Neurology (in press)"},{"key":"3059_CR26","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1191\/1352458505ms1196oa","volume":"11","author":"Fazekas","year":"2005","unstructured":"Fazekas F, Sorensen PS, Filippi M et al (2005) MRI results from the European Study on Intravenous Immunoglobulin in Secondary Progressive Multiple Sclerosis (ESIMS). Mult Scler 11:433\u2013440","journal-title":"Mult Scler"},{"key":"3059_CR27","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1001\/archneur.61.9.1409","volume":"61","author":"Filippi","year":"2004","unstructured":"Filippi M, Rocca MA, Pagani E et al (2004) European study on intravenous immunoglobulin in multiple sclerosis. Results of magnetization transfer magnetic resonance imaging analysis. Arch Neurol 61:1409\u20131412","journal-title":"Arch Neurol"},{"key":"3059_CR28","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jns.2006.08.007","volume":"251","author":"Fox","year":"2006","unstructured":"Fox RJ, Costello F, Judkins AR et al (2006) Treatment of Susac syndrome with gamma globulin and corticosteroids. J Neurol Sci 251:17\u201322","journal-title":"J Neurol Sci"},{"key":"3059_CR29","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1007\/s00415-007-0594-8","volume":"254","author":"Fronczek","year":"2007","unstructured":"Fronczek R, Verschuuren J, Lammers GJ (2007) Response to intravenous immunoglobulins and placebo in a patient with narcolepsy with cataplexy. J Neurol 254:1607\u20131608","journal-title":"J Neurol"},{"key":"3059_CR30","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1212\/01.wnl.0000318277.25679.9e","volume":"71","author":"Fu","year":"2008","unstructured":"Fu DC, Montgomery JR (2008) High-dose, rapid-infusion IVIG in postvaccination acute disseminated encephalomyelitis. Neurology 71:294\u2013295","journal-title":"Neurology"},{"key":"3059_CR31","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1007\/s00415-006-0199-7","volume":"253","author":"Fumal","year":"2006","unstructured":"Fumal A, Jobe J, Pepin J-L et al (2006) Intravenous immunoglobulins in paraneoplastic brainstem encephalitis with anti-Ri antibodies. J Neurol 253:1360\u20131361","journal-title":"J Neurol"},{"key":"3059_CR32","doi-asserted-by":"crossref","unstructured":"Gajdos P, Chevret S, Toyka K (2008) Intravenous immunoglobulin for myasthenia gravis. Cochrane Database Syst Rev CD002277","DOI":"10.1002\/14651858.CD002277.pub3"},{"key":"3059_CR33","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1001\/archneur.62.11.1689","volume":"62","author":"Gajdos","year":"2005","unstructured":"Gajdos P, Tranchant C, Clair B et al (2005) Treatment of myasthenia gravis exacerbation with intravenous immunoglobulins. Arch Neurol 62:1689\u20131693","journal-title":"Arch Neurol"},{"key":"3059_CR34","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1136\/jnnp.2004.047688","volume":"76","author":"Ghosh","year":"2005","unstructured":"Ghosh A, Busby M, Kennett R et al (2005) A practical definition of conduction block in IvIg responsive multifocal motor neuropathy. J Neurol Neurosurg Psychiatry 76:1264\u20131268","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"3059_CR35","doi-asserted-by":"crossref","unstructured":"Goebel A, Moore A, Weatherall R et al (2003) Intravenous immunoglobulin in the treatment of primary trigeminal neuralgia refractory to carbamazepin: a study protocol. BMC Neurology 3","DOI":"10.1186\/1471-2377-3-1"},{"key":"3059_CR36","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1046\/j.1526-4637.2002.02018.x","volume":"3","author":"Goebel","year":"2002","unstructured":"Goebel A, Netal S, Schedel R, Sprotte G (2002) Human pooled immunoglobulin in the treatment of chronic pain syndromes. Pain Med 3:119\u2013127","journal-title":"Pain Med"},{"key":"3059_CR37","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1002\/ana.20400","volume":"57","author":"Goebel","year":"2005","unstructured":"Goebel A, Stock M, Deacon R et al (2005) Intravenous immunoglobulin response and evidence for pathogenic antibodies in a case of complex regional pain syndrome 1. Ann Neurol 57:463\u2013464","journal-title":"Ann Neurol"},{"key":"3059_CR38","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jneuroim.2004.01.010","volume":"150","author":"Gonzalez","year":"2004","unstructured":"Gonzalez H, Khademi M, Andersson M et al (2004) Prior poliomyelitis-IvIg treatment reduces proinflammatory cytokine production. J Neuroimmunol 150:139\u2013144","journal-title":"J Neuroimmunol"},{"key":"3059_CR39","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S1474-4422(06)70447-1","volume":"5","author":"Gonzalez","year":"2006","unstructured":"Gonzalez H, Sunnerhagen KS, Sj\u00f6berg I et al (2006) Intravenous immunoglobulin for post-polio syndrome: a randomised controlled trial. Lancet Neurol 5:493\u2013500","journal-title":"Lancet Neurol"},{"key":"3059_CR40","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1177\/1352458506075654","volume":"13","author":"Haas","year":"2007","unstructured":"Haas J, Hommes OR (2007) A dose comparison study of IVIg in postpartum relapsing-remitting multiple sclerosis. Mult Scler 13:900\u2013908","journal-title":"Mult Scler"},{"key":"3059_CR41","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1191\/1352458505ms1224oa","volume":"11","author":"Haas","year":"2005","unstructured":"Haas J, Maas-Enriquez M, Hartung H-P (2005) Intravenous immunoglobulins in the treatment of relapsing-remitting multiple sclerosis \u2013 results of a retrospective multicenter observational study over five years. Mult Scler 11:562\u2013567","journal-title":"Mult Scler"},{"key":"3059_CR42","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1111\/j.1468-1331.2009.02568.x","volume":"16","author":"Harbo","year":"2009","unstructured":"Harbo T, Andersen H, Hess A et al (2009) Subcutaneous versus intravenous immunoglobulin in multifocal motor neuropathy: a randomized, single-blinded cross-over trial. Eur J Neurol 16:631\u2013638","journal-title":"Eur J Neurol"},{"key":"3059_CR43","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S0140-6736(04)17101-8","volume":"364","author":"Hommes","year":"2004","unstructured":"Hommes OR, Sorensen PS, Fazekas F et al (2004) Intravenous immunoglobulin in secondary progressive multiple sclerosis: randomised placebo-controlled trial. Lancet 364:1149\u20131156","journal-title":"Lancet"},{"key":"3059_CR44","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/j.1468-1331.2006.01278.x","volume":"13","author":"Hughes","year":"2006","unstructured":"Hughes RA, Bouche P, Cornblath DR et al (2006) European Federation of Neurological Societies\/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. Eur J Neurol 13:326\u2013332","journal-title":"Eur J Neurol"},{"key":"3059_CR45","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/S1474-4422(07)70329-0","volume":"7","author":"Hughes","year":"2008","unstructured":"Hughes RAC, Donofrio P, Bril V et al (2008) Intravenous immunoglobulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. Lancet Neurol 7:136\u2013144","journal-title":"Lancet Neurol"},{"key":"3059_CR46","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1093\/brain\/awm004","volume":"130","author":"Hughes","year":"2007","unstructured":"Hughes RAC, Swan AV, Rapha\u00ebl J-C et al (2007) Immunotherapy for Guillain-Barr\u00e9 syndrome: a systematic review. Brain 130:2245\u20132257","journal-title":"Brain"},{"key":"3059_CR47","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1212\/01.WNL.0000158680.89323.F8","volume":"64","author":"Iijima","year":"2005","unstructured":"Iijima M, Yamamoto M, Hirayama M et al (2005) Clinical and electrophysiologic correlates of IVIg responsiveness in CIDP. Neurology 64:1471\u20131475","journal-title":"Neurology"},{"key":"3059_CR48","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1001\/archneur.65.11.noc80069","volume":"65","author":"Jacob","year":"2008","unstructured":"Jacob A, Weinshenker BG, Violich I et al (2008) Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch Neurol 65:1443\u20131448","journal-title":"Arch Neurol"},{"key":"3059_CR49","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1136\/jnnp.2008.149013","volume":"80","author":"Jann","year":"2009","unstructured":"Jann S, Bramerio MA, Facchetti D, Sterzi R (2009) Intravenous immunoglobulin is effective in patients with diabetes and with chronic inflammatory demyelinating polyneuropathy: long term follow-up. J Neurol Neurosurg Psychiatry 80:70\u201373","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"3059_CR50","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1097\/CND.0b013e3181660807","volume":"9","author":"Jensen","year":"2008","unstructured":"Jensen P, Bril V (2008) A comparison of the effectiveness of intravenous immunoglobulin and plasma exchange as preoperative therapy of myasthenia gravis. J Clin Neuromuscul Dis 9:352\u2013355","journal-title":"J Clin Neuromuscul Dis"},{"key":"3059_CR51","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1111\/j.1085-9489.2005.10302.x","volume":"10","author":"Joint","year":"2005","unstructured":"Joint Task Force of the EFNS and the PNS (2005) European Federation of Neurological Societies\/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. J Peripher Nerv Syst 10:220\u2013228","journal-title":"J Peripher Nerv Syst"},{"key":"3059_CR52","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1085-9489.2006.00058.x","volume":"11","author":"Joint","year":"2006","unstructured":"Joint Task Force of the EFNS and the PNS (2006) European Federation of Neurological Societies\/Peripheral Nerve Society Guideline on management of multifocal motor neuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. J Peripher Nerv Syst 11:1\u20138","journal-title":"J Peripher Nerv Syst"},{"key":"3059_CR53","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.autrev.2006.08.011","volume":"6","author":"Katz","year":"2007","unstructured":"Katz U, Achiron A, Sherer Y, Shoenfeld Y (2007) Safety of intravenous immunoglobulin (IVIG) therapy. Autoimmun Rev 6:257\u2013259","journal-title":"Autoimmun Rev"},{"key":"3059_CR54","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1136\/jnnp.2005.084533","volume":"77","author":"Kizawa","year":"2006","unstructured":"Kizawa M, Mori K, Iijima M et al (2006) Intravenous immunoglobulin treatment in painful sensory neuropathy without sensory ataxia associated with Sjogren\u2019s syndrome. J Neurol Neurosurg Psychiatry 77:967\u2013969","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"3059_CR55","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1007\/s00415-006-0258-0","volume":"253","author":"K\u00f6ller","year":"2006","unstructured":"K\u00f6ller H, Schroeter M, Feischen H et al (2006) Subcutaneous self-infusions of immunoglobulins as a potential therapeutic regimen in immune-mediated neuropathies. J Neurol 253:1505\u20131506","journal-title":"J Neurol"},{"key":"3059_CR56","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1001\/archneurol.2009.132","volume":"66","author":"Langer-Gould","year":"2009","unstructured":"Langer-Gould A, Huang SM, Gupta R et al (2009) Exclusive breastfeeding and the risk of postpartum relapses in women with multiple sclerosis. Arch Neurol 66:958\u2013963","journal-title":"Arch Neurol"},{"key":"3059_CR57","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1002\/mus.20909","volume":"37","author":"Lee","year":"2008","unstructured":"Lee H-H, Linker RA, Paulus W et al (2008) Subcutaneous immunoglobulin infusion: a new therapeutic option in chronic inflammatory demyelinating polyneuropathy. Muscle Nerve 37:406\u2013409","journal-title":"Muscle Nerve"},{"key":"3059_CR58","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1136\/jnnp.2007.121756","volume":"79","author":"Leger","year":"2008","unstructured":"Leger J-M, Viala K, Cancalon F et al (2008) Intravenous immunoglobulin as short- and long-term therapy of multifocal motor neuropathy: a retrospective study of response to IVIg and of its predictive criteria in 40 patients. J Neurol Neurosurg Psychiatry 79:93\u201396","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"3059_CR59","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1084\/jem.20050304","volume":"202","author":"Lennon","year":"2005","unstructured":"Lennon VA, Kryzer TJ, Pittock SJ et al (2005) IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 202:473\u2013477","journal-title":"J Exp Med"},{"key":"3059_CR60","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1196\/annals.1361.121","volume":"1051","author":"Levy","year":"2005","unstructured":"Levy Y, Uziel Y, Zandman G et al (2005) Response of vasculitic peripheral neuropathy to intravenous immunoglobulin. Ann N Y Acad Sci 1051:779\u2013786","journal-title":"Ann N Y Acad Sci"},{"key":"3059_CR61","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1212\/WNL.51.4.1219","volume":"51","author":"Mandler","year":"1998","unstructured":"Mandler RN, Ahmed W, Dencoff JE (1998) Devic\u2019s neuromyelitis optica: a prospective study of seven patients treated with prednisone and azathioprine. Neurology 51:1219\u20131220","journal-title":"Neurology"},{"key":"3059_CR62","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1002\/art.23147","volume":"58","author":"Martinez","year":"2008","unstructured":"Martinez V, Cohen P, Pagnoux C et al (2008) Intravenous immunoglobulins for relapses of systemic vasculitides associated with antineutrophil cytoplasmic autoantibodies: results of a multicenter, prospective, open-label study of twenty-two patients. Arthritis Rheum 58:308\u2013317","journal-title":"Arthritis Rheum"},{"key":"3059_CR63","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1212\/WNL.0b013e3181a0fd80","volume":"72","author":"Merkies","year":"2009","unstructured":"Merkies ISJ, Bril V, Dalakas MC et al (2009) Health-related qualiti-of-life improvements in CIDP with immune globulin IV 10%. The ICE study. Neurology 72:1337\u20131344","journal-title":"Neurology"},{"key":"3059_CR64","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1007\/s10067-004-1046-9","volume":"24","author":"Milstone","year":"2005","unstructured":"Milstone AM, Meyers K, Elia J (2005) Treatment of acute neuropsychiatric lupus with intravenous immunoglobulin (IVIG): a case report and review of the literature. Clin Rheumatol 24:394\u2013397","journal-title":"Clin Rheumatol"},{"key":"3059_CR65","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1212\/01.wnl.0000258673.31824.61","volume":"68","author":"Mori","year":"2007","unstructured":"Mori M, Kuwabara S, Fukutake T, Hattori T (2007) Intravenous immunoglobulin therapy for Miller Fisher syndrome. Neurology 68:1144\u20131146","journal-title":"Neurology"},{"key":"3059_CR66","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jns.2008.12.018","volume":"279","author":"Morozumi","year":"2009","unstructured":"Morozumi S, Kawagashira Y, Iijima M et al (2009) Intravenous immunoglobulin treatment for painful sensory neuropathy associated with Sjogren\u2019s syndrome. J Neurol Sci 279:57\u201361","journal-title":"J Neurol Sci"},{"key":"3059_CR67","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1007\/s00115-006-2220-x","volume":"77","author":"Multiple","year":"2006","unstructured":"Multiple Sklerose Therapie Konsensus Gruppe (2006) Immunmodulatorische Studientherapie der Multiplen Sklerose. Aktuelle Therapieempfehlungen (September 2006). Nervenarzt 77:1506\u20131518","journal-title":"Nervenarzt"},{"key":"3059_CR68","doi-asserted-by":"crossref","first-page":"12254","DOI":"10.1021\/bi801767k","volume":"47","author":"O","year":"2008","unstructured":"O\u2019Nuallain B, Acero L, Williams AD et al (2008) Human plasma contains cross-reactive Abeta conformer-specific IgG antibodies. Biochemistry 47:12254\u201312256","journal-title":"Biochemistry"},{"key":"3059_CR69","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.2169\/internalmedicine.46.0217","volume":"46","author":"Okada","year":"2007","unstructured":"Okada K, Tsuji S, Tanaka K (2007) Intermittent intravenous immunoglobulin successfully prevents relapses of neuromyelitis optica. Intern Med 46:1671\u20131672","journal-title":"Intern Med"},{"key":"3059_CR70","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1371\/journal.pmed.0040133","volume":"4","author":"Paul","year":"2007","unstructured":"Paul F, Jarius S, Aktas O et al (2007) Antibody to aquaporin-4 in the diagnosis of neuromyelitis optica. PLoS Med 4:133","journal-title":"PLoS Med"},{"key":"3059_CR71","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s11060-006-9198-x","volume":"81","author":"Phuphanich","year":"2007","unstructured":"Phuphanich S, Brock C (2007) Neurologic improvement after high-dose intravenous immunoglobulin therapy in patients with paraneoplastic cerebellar degeneration associated with anti-Purkinje cell antibody. J Neurooncol 81:67\u201369","journal-title":"J Neurooncol"},{"key":"3059_CR72","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1093\/brain\/awm144","volume":"130","author":"Piepers","year":"2007","unstructured":"Piepers S, Van den Berg-Vos R, Van der Pol W-L et al (2007) Mycophenolate mofetil as adjunctive therapy for MMN patients: a randomized controlled trial. Brain 130:2004\u20132010","journal-title":"Brain"},{"key":"3059_CR73","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1177\/1352458507078400","volume":"13","author":"P\u00f6hlau","year":"2007","unstructured":"P\u00f6hlau D, Przuntek H, Sailer M et al (2007) Intravenous immunoglobulin in primary and secondary chronic progressive multiple sclerosis: a randomized placebo controlled multicentre study. Mult Scler 13:1107\u20131117","journal-title":"Mult Scler"},{"key":"3059_CR74","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0022-510X(99)00072-6","volume":"165","author":"Pradhan","year":"1999","unstructured":"Pradhan S, Gupta RP, Shashank S, Pandey N (1999) Intravenous immunoglobulin therapy in acute disseminated encephalomyelitis. J Neurol Sci 165:56\u201361","journal-title":"J Neurol Sci"},{"key":"3059_CR75","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1007\/s00415-006-0378-6","volume":"254","author":"Rajabally","year":"2007","unstructured":"Rajabally YA, Seow H, Abbott RJ (2007) Immunoglobulin-responsive dysautonomia in Sjogren\u2019s syndrome. J Neurol 254:674\u2013675","journal-title":"J Neurol"},{"key":"3059_CR76","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/j.1529-8027.2006.00105.x","volume":"11","author":"Rajabally","year":"2006","unstructured":"Rajabally YA, Seow H, Wilson P (2006) Dose of intravenous immunoglobulins in chronic inflammatory demyelinating polyneuropathy. J Peripher Nerv Syst 11:325\u2013329","journal-title":"J Peripher Nerv Syst"},{"key":"3059_CR77","doi-asserted-by":"crossref","unstructured":"Ravaglia S, Ceroni M, Moglia A et al (2004) Post-infectious and post-vaccinal acute disseminated encephalomyelitis occurring in the same patients J Neurol 251:1147\u20131150","DOI":"10.1007\/s00415-004-0498-9"},{"key":"3059_CR78","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1007\/s00415-007-0561-4","volume":"254","author":"Ravaglia","year":"2007","unstructured":"Ravaglia S, Piccolo G, Ceroni M et al (2007) Severe steroid-resistant post-infectious encephalomyelitis: general features and effects of IVIg. J Neurol 254:1518\u20131523","journal-title":"J Neurol"},{"key":"3059_CR79","doi-asserted-by":"crossref","unstructured":"Relkin NR, Szabo P, Adamiak B et al (2010) 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease. Neurobiol Aging (in press)","DOI":"10.1016\/j.neurobiolaging.2007.12.021"},{"key":"3059_CR80","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1212\/01.WNL.0000152873.82631.B3","volume":"64","author":"Roed","year":"2005","unstructured":"Roed HG, Langkilde A, Sellebjerg FT et al (2005) A double-blind, randomized trial of IV immunoglobulin treatment in acute optic neuritis. Neurology 64:804\u2013810","journal-title":"Neurology"},{"key":"3059_CR81","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1212\/01.WNL.0000145706.04340.25","volume":"63","author":"R\u00fcegg","year":"2004","unstructured":"R\u00fcegg SJ, Fuhr P, Steck AJ (2004) Rituximab stabilizes multifocal motor neuropathy increasingly less responsive to IVIg. Neurology 63:2178\u20132179","journal-title":"Neurology"},{"key":"3059_CR82","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s10165-007-0013-0","volume":"18","author":"Saito","year":"2008","unstructured":"Saito E, Koike T, Hashimoto H et al (2008) Efficacy of high-dose intravenous immunoglobulin therapy in Japanese patients with steroid-resistant polymyositis and dermatomyositis. Mod Rheumatol 18:34\u201344","journal-title":"Mod Rheumatol"},{"key":"3059_CR83","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1007\/s10067-008-0892-2","volume":"27","author":"Schleinitz","year":"2008","unstructured":"Schleinitz N, Jean E, Benarous L et al (2008) Subcutaneous immunoglobulin administration: an alternative to intravenous infusion as adjuvant treatment for dermatomyositis? Clin Rheumatol 27:1067\u20131068","journal-title":"Clin Rheumatol"},{"key":"3059_CR84","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1111\/j.1600-0404.2007.00877.x","volume":"116","author":"Shibata-Hamaguchi","year":"2007","unstructured":"Shibata-Hamaguchi A, Samuraki M, Furui E et al (2007) Long-term effect of intravenous immunoglobulin on anti-MuSK antibodypositive myasthenia gravis. Acta Neurol Scand 116:406\u2013408","journal-title":"Acta Neurol Scand"},{"key":"3059_CR85","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/ncpneuro0300","volume":"2","author":"Siegel","year":"2006","unstructured":"Siegel JM, Boehmer LN (2006) Narcolepsy and the hypocretin system \u2013 where motion meets emotion. Nat Clin Pract Neurol 2:548\u2013556","journal-title":"Nat Clin Pract Neurol"},{"key":"3059_CR86","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1111\/j.1468-1331.2006.01476.x","volume":"13","author":"Skeie","year":"2006","unstructured":"Skeie GO, Apostolski S, Evoli A et al (2006) Guidelines for the treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol 13:691\u2013699","journal-title":"Eur J Neurol"},{"key":"3059_CR87","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1212\/01.wnl.0000277697.55288.d0","volume":"69","author":"Slee","year":"2007","unstructured":"Slee M, Selvan A, Donaghy M (2007) Multifocal motor neuropathy. The diagnostic spectrum and response to treatment. Neurology 69:1680\u20131687","journal-title":"Neurology"},{"key":"3059_CR88","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1212\/01.WNL.0000145798.61383.39","volume":"63","author":"Sorensen","year":"2004","unstructured":"Sorensen PS, Haas J, Sellebjerg F et al (2004) IV immunoglobulins as add-on treatment to methylprednisolone for acute relapses in MS. Neurology 63:2028\u20132033","journal-title":"Neurology"},{"key":"3059_CR89","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1471-2377-7-3","volume":"7","author":"Sparks","year":"2007","unstructured":"Sparks S, Rakocevic G, Joe G et al (2007) Intravenous immune globuline in hereditary inclusion body myopathy: a pilot study. BMC Neurology 7:3","journal-title":"BMC Neurology"},{"key":"3059_CR90","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s00115-004-1733-4","volume":"75","author":"Stangel","year":"2004","unstructured":"Stangel M, Gold R (2004) Einsatz von i.v. Immunglobulinen in der Neurologie. Ein evidenzbasierter Konsens. Nervenarzt 75:801\u2013815","journal-title":"Nervenarzt"},{"key":"3059_CR91","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1007\/s00115-005-1935-4","volume":"76","author":"Stangel","year":"2005","unstructured":"Stangel M, Gold R (2005) Hochdosierte intraven\u00f6se Immunglobuline in der Behandlung der Multiplen Sklerose. Update \u00fcber neue Studien. Nervenarzt 76:1267\u20131272","journal-title":"Nervenarzt"},{"key":"3059_CR92","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.nmd.2009.04.013","volume":"19","author":"Stieglbauer","year":"2009","unstructured":"Stieglbauer K, Topakian R, Hinterberger G, Aichner FT (2009) Beneficial effect of rituximab monotherapy in multifocal motor neuropathy. Neuromuscul Disord 19:473\u2013475","journal-title":"Neuromuscul Disord"},{"key":"3059_CR93","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/j.1468-1331.2006.01142.x","volume":"13","author":"Strigl-Pill","year":"2006","unstructured":"Strigl-Pill N, K\u00f6nig A, Schr\u00f6der M et al (2006) Prediction of response to IVIg treatment in patients with lower motor neurone disorders. Eur J Neurol 13:135\u2013140","journal-title":"Eur J Neurol"},{"key":"3059_CR94","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1007\/s00115-004-1842-0","volume":"76","author":"St\u00fcve","year":"2005","unstructured":"St\u00fcve O, Nessler S, Hartung HP et al (2005) Acute disseminated encephalomyelitis. Pathogenesis, diagnosis, treatment and prognosis. Nervenarzt 76:701\u2013707","journal-title":"Nervenarzt"},{"key":"3059_CR95","doi-asserted-by":"crossref","first-page":"4788","DOI":"10.1073\/pnas.0807319106","volume":"106","author":"Tackenberg","year":"2009","unstructured":"Tackenberg B, Jelcic I, Baerenwaldt A et al (2009) Impaired inhibitory Fc\u03b3 receptor IIB expression on B cells in chronic inflammatory demyelinating polyneuropathy. Proc Natl Acad Sci 106:4788\u20134792","journal-title":"Proc Natl Acad Sci"},{"key":"3059_CR96","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1212\/01.wnl.0000260972.07422.ea","volume":"68","author":"Tackenberg","year":"2007","unstructured":"Tackenberg B, L\u00fcnemann JD, Steinbrecher A et al (2007) Classifications and treatment responses in chronic immune-mediated demyelinating polyneuropathy. Neurology 68:1622\u20131629","journal-title":"Neurology"},{"key":"3059_CR97","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.jns.2006.05.065","volume":"247","author":"Takahashi","year":"2006","unstructured":"Takahashi H, Kawaguchi N, Hattori N (2006) High-dose intravenous immunoglobulin for the treatment of MuSK antibody-positive, seronegative myasthenia gravis. J Neurol Sci 247:239\u2013241","journal-title":"J Neurol Sci"},{"key":"3059_CR98","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1212\/01.WNL.0000110185.23464.A1","volume":"62","author":"Terenghi","year":"2004","unstructured":"Terenghi F, Cappellari A, Bersano A et al (2004) How long is IVIg effective in multifocal motor neuropathy? Neurology 62:666\u2013668","journal-title":"Neurology"},{"key":"3059_CR99","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1111\/j.1468-1331.2008.02258.x","volume":"15","author":"Tselis","year":"2008","unstructured":"Tselis A, Perumal J, Caon C et al (2008) Treatment of corticosteroid refractory optic neuritis in multiple sclerosis patients with intravenous immunoglobulins. Eur J Neurol 15:1163\u20131167","journal-title":"Eur J Neurol"},{"key":"3059_CR100","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1046\/j.1442-200x.2004.01872.x","volume":"46","author":"Unay","year":"2004","unstructured":"Unay B, Sarici SU, Bulakbasi N et al (2004) Intravenous immunoglobulin therapy in acute disseminated encephalomyelitis associated with hepatitis A infection. Pediatr Int 46:171\u2013173","journal-title":"Pediatr Int"},{"key":"3059_CR101","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1007\/s00415-008-0996-2","volume":"255","author":"Valko","year":"2008","unstructured":"Valko PO, Khatami R, Baumann CR, Bassetti CL (2008) No persistent effect of intravenous immunoglobulins in patients with narcolepsy with cataplexy. J Neurol 255:1900\u20131903","journal-title":"J Neurol"},{"key":"3059_CR102","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/S0140-6736(03)15324-X","volume":"363","author":"Van","year":"2004","unstructured":"Van Koningsveld R, Schmitz PIM, Mech\u00e9 FGA van der et al (2004) Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barr\u00e9 syndrome: randomised trial. Lancet 363:192\u2013196","journal-title":"Lancet"},{"key":"3059_CR103","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1111\/j.1468-1331.2006.01266.x","volume":"13","author":"Vedeler","year":"2006","unstructured":"Vedeler CA, Antoine JC, Giometto B et al (2006) Management of paraneoplastic neurological syndromes: report of an EFNS Task Force. Eur J Neurol 13:682\u2013690","journal-title":"Eur J Neurol"},{"key":"3059_CR104","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1093\/brain\/awh222","volume":"127","author":"Viala","year":"2004","unstructured":"Viala K, Renie L, Maisonobe T et al (2004) Follow-up study and response to treatment in 23 patients with Lewis-Sumner syndrome. Brain 127:2010\u20132017","journal-title":"Brain"},{"key":"3059_CR105","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1191\/1352458504ms978sr","volume":"10","author":"Visser","year":"2004","unstructured":"Visser LH, Beekman R, Tijssen CC et al (2004) A randomized, double-blind, placebo-controlled pilot study of i.v. immune globulins in combination i.v. methylprednisolone in the treatment of relapses in patients with MS. Mult Scler 10:89\u201391","journal-title":"Mult Scler"},{"key":"3059_CR106","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s00415-006-5005-z","volume":"253","author":"Voltz","year":"2006","unstructured":"Voltz R (2006) Intravenous immunoglobulin therapy in paraneoplastic neurological syndromes. J Neurol 253(Suppl 5):33\u201338","journal-title":"J Neurol"},{"key":"3059_CR107","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1212\/01.WNL.0000140497.85952.FA","volume":"63","author":"Vucic","year":"2004","unstructured":"Vucic S, Black KR, Siao Tick Chong P, Cros D (2004) Multifocal motor neuropathy. Decrease in conduction block and reinnervation with long-term IVIg. Neurology 63:1264\u20131269","journal-title":"Neurology"},{"key":"3059_CR108","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s10165-009-0180-2","volume":"19","author":"Wakasugi","year":"2009","unstructured":"Wakasugi D, Kato T, Gono T et al (2009) Extreme efficacy of intravenous immunoglobulin therapy for severe burning pain in a patient with small fiber neuropathy associated with primary Sjogren\u2019s syndrome. Mod Rheumatol 19:437\u2013440","journal-title":"Mod Rheumatol"},{"key":"3059_CR109","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1002\/jnr.21217","volume":"85","author":"Warrington","year":"2007","unstructured":"Warrington AE, Bieber AJ, Ciric B et al (2007) A recombinant human IgM promotes myelin repair after a single, very low dose. J Neurosci Res 85:967\u2013976","journal-title":"J Neurosci Res"},{"key":"3059_CR110","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1001\/archneur.63.7.957","volume":"63","author":"Weinstock-Guttman","year":"2006","unstructured":"Weinstock-Guttman B, Ramanathan M, Lincoff N et al (2006) Study of mitoxantrone for the treatment of recurrent neuromyelitis optica (Devic disease). Arch Neurol 63:957\u2013963","journal-title":"Arch Neurol"},{"key":"3059_CR111","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1212\/01.wnl.0000256698.69121.45","volume":"68","author":"Zinman","year":"2007","unstructured":"Zinman L, Ng E, Bril V (2007) IV immunoglobulin in patients with myasthenia gravis. A randomized controlled trial. Neurology 68:837\u2013841","journal-title":"Neurology"}],"container-title":["Der Nervenarzt"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-010-3059-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00115-010-3059-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-010-3059-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,30]],"date-time":"2019-05-30T11:31:03Z","timestamp":1559215863000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00115-010-3059-8"}},"subtitle":["Ein evidenzbasierter Konsens: Update 2010"],"short-title":[],"issued":{"date-parts":[[2010,6,26]]},"references-count":111,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,4]]}},"alternative-id":["3059"],"URL":"https:\/\/doi.org\/10.1007\/s00115-010-3059-8","relation":{},"ISSN":["0028-2804","1433-0407"],"issn-type":[{"value":"0028-2804","type":"print"},{"value":"1433-0407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,6,26]]}}}